NASDAQ:LXEO • US52886X1072
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LEXEO THERAPEUTICS INC (LXEO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-18 | Raymond James | Initiate | Strong Buy |
| 2025-12-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-11-20 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-11-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-15 | Guggenheim | Initiate | Buy |
| 2025-10-07 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-10-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-31 | Oppenheimer | Initiate | Outperform |
| 2025-05-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-25 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-24 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 520K | 1.66M 219.23% | 650K -60.84% | -100.00% | 14.092M | 94.371M 569.68% | 306.33M 224.60% | 601.09M 96.22% | 866.82M 44.21% | 1.076B 24.13% | 1.193B 10.87% | ||||
| EBITDA YoY % growth | -4.59M | -50.63M -1,003.05% | -60.24M -18.98% | -73.44M -12.78% | -102M -55.10% | -112.2M -6.48% | -118.32M -5.45% | -139.74M -18.10% | -157.08M -12.41% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.59M | -50.64M -1,003.27% | -60.51M -19.49% | -72.634M -13.23% | -109.29M -54.72% | -113.439M -7.02% | -117.428M -3.52% | -125.291M -6.70% | -51.006M 59.29% | 64.465M 226.39% | 296.36M 359.72% | 484.66M 63.54% | 654.34M 35.01% | 702.91M 7.42% | |
| Operating Margin | -882.69% | -3,050.60% | -9,309.23% | N/A | N/A | N/A | N/A | -889.09% | -54.05% | 21.04% | 49.30% | 55.91% | 60.81% | 58.92% | |
| EPS YoY % growth | N/A | N/A | N/A | -4.12 | -3.18 25.32% | -2.01 28.90% | -1.37 37.40% | -1.39 -1.19% | -0.88 36.76% | 0.30 133.72% | 2.00 574.72% | 3.79 89.95% | 5.42 43.05% | 6.85 26.39% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 67.72% | -0.34 43.90% | -0.36 -7.84% | -0.37 -37.68% | -0.47 -48.41% | -0.46 -36.36% | -0.47 -31.85% | -0.44 -17.99% |
| Revenue Q2Q % growth | 7.181M | |||||||
| EBITDA Q2Q % growth | -25.5M 24.25% | -28.56M 5.97% | -30.6M -44.66% | -33.66M -49.41% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -26.25M 22.35% | -27.662M 9.76% | -29.171M -35.13% | -30.908M -33.71% | -37.71M -43.66% | -37.45M -35.39% | -39.221M -34.45% | -39.411M -27.51% |
All data in USD
17 analysts have analysed LXEO and the average price target is 19.99 USD. This implies a price increase of 251.97% is expected in the next year compared to the current price of 5.68.
LEXEO THERAPEUTICS INC (LXEO) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of LEXEO THERAPEUTICS INC (LXEO) is -0.32 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering LEXEO THERAPEUTICS INC (LXEO) is 17.